Viking Therapeutics
VKTX
137 hedge funds and large institutions have $184M invested in Viking Therapeutics in 2020 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 40 increasing their positions, 40 reducing their positions, and 23 closing their positions.
203% more call options, than puts
Call options by funds: $7.19M | Put options by funds: $2.37M
0% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 40
0.8% less ownership
Funds ownership: 55.05% → 54.25% (-0.8%)
4% less funds holding
Funds holding: 143 → 137 (-6)
13% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 23
42% less capital invested
Capital invested by funds: $319M → $184M (-$135M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aviva
London,
United Kingdom
|
+$3.66M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.84M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.49M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.06M |
| 5 |
B
Bailard
Foster City,
California
|
+$846K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$4.61M |
| 2 |
AG
Artal Group
Luxembourg
|
-$2.81M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.7M |
| 4 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$1.54M |
| 5 |
SC
Sculptor Capital
New York
|
-$1.39M |
VKTX Hedge Fund Activity: Q1 2020 in Review
137 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q1 2020, worth a combined $184M — down 42% from $319M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of VKTX and 20 opened new positions — a net loss of 3 holders — while 40 trimmed existing stakes and 40 added.
The largest buyer was Aviva, opening a new position worth an estimated $3.66M. The largest seller was American Century Companies, exiting entirely with an estimated $4.61M sold.
- 137 institutional investors held Viking Therapeutics (VKTX) as of Q1 2020, down from 143 in Q4 2019.
- Funds reported $184M of Viking Therapeutics stock for Q1 2020, down 42% quarter-over-quarter.
- 20 funds opened new Viking Therapeutics positions in Q1 2020 and 23 closed out, a net change of -3 holders.
- The largest Viking Therapeutics buyer in Q1 2020 was Aviva, an estimated $3.66M added.
- The largest Viking Therapeutics seller in Q1 2020 was American Century Companies, an estimated $4.61M sold.
Based on aggregated 13F filings for Q1 2020.